Article
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Onkologie - 1 Dec 2004
Lazar A, Mau-Holzmann U A, Kolb H, Reichenmiller H E, Riess O, Schömig E
Abstract excerpt
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the metabolism of the chemotherapeutic drug 5-fluorouracil (5-FU). Application of 5-FU is restricted by a narrow therapeutic index because of severe toxicity of WHO grades III-IV. The exon 14-skipping mutation (c.1905+1G>A) accounts for approximately a quarter of all severely toxic cases. However, numerous other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.